Last reviewed · How we verify
Prostate hyperplasia medication
The prostate hyperplasia medication developed by Turku University Hospital is currently marketed, positioning it as an active player in the treatment of this condition. A key strength is the protection afforded by the key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the lack of disclosed revenue and key trial results, which may limit the drug's competitive visibility and investor confidence.
At a glance
| Generic name | Prostate hyperplasia medication |
|---|---|
| Also known as | Finasteride 5 MG, Dutasteride 0,5 MG, Dutasteride and Tamsulosin 0,5/0,4 MG |
| Sponsor | Turku University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (NA)
- Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests (PHASE3)
- A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate (PHASE4)
- Study on the Effectiveness of Tranilast in the Treatment of Medium to Large Volume Benign Prostatic Hyperplasia (EARLY_PHASE1)
- Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH
- Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter (PHASE2)
- A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostate hyperplasia medication CI brief — competitive landscape report
- Prostate hyperplasia medication updates RSS · CI watch RSS
- Turku University Hospital portfolio CI